基于动物实验系统评价大黄素治疗糖尿病肾病的可行性OACSTPCD

Objective:To systematically evaluate the protective effect of emodin on the kidney of diabetes nephropathy ani-mals.Methods:The databases of CNKI,VIP,Wanfang,Chinese biomedical literature and PubMed were searched by computer,and the animal experiments of emodin in the treatment of diabetes nephropathy from the establishment of the database to February 25,2023 were searched.RevMan 5.4.1 software was used for analysis.Results:Totally 12 studies were included.The results showed that compared with the control group,the emodin group was more effective in reducing blood glucose[SMD=-2.51,95%CI(-3.77,-1.24),I2=89%],creatinine[SMD=-3.05,95%CI(-4.75,-1.34),I2=91%],urea nitrogen[SMD=-2.69,95%CI(-3.88,-1.50),I2=82%],24 h urine protein quantification[SMD=-3.35,95%CI(-4.85,-1.85),I2= 87%],relative kidney weight[SMD =-7.72,95%CI(-12.55,-2.88),I2=90%],triacylglycerol[SMD=-1.24,95%CI(-1.94,-0.54),I2=0%]and other indicators.There was no significant difference between the emodin and control groups in cho-lesterol[SMD=-1.19,95%CI(-2.29,-0.55),I2=77%].At the same time,meta-analysis showed that emodin protection of kidney was related to the expression of nephrin and related signal pathways.Few serious adverse reactions related to such studies have been reported.Conclusion:Emodin has a protective effect on the kidney of diabetes nephropathy animals,but it needs to be further confirmed by a large sample clinical trial with higher quality and strict specifications.